Browsing Tag
Fabry disease
3 posts
Can fewer infusions improve adherence in Fabry disease enzyme replacement therapy?
EU approves monthly Elfabrio dosing for Fabry disease. Discover how reduced infusion frequency could reshape enzyme therapy and treatment burden.
Sangamo Therapeutics shares surge 13% after FDA accepts rolling BLA for ST‑920 in Fabry disease
Sangamo Therapeutics shares surged 13% as the FDA accepted a rolling BLA for ST‑920 in Fabry disease. Learn what this milestone means and what’s next.
Protalix BioTherapeutics receives FDA extension for pegunigalsidase alfa review: What this means for Fabry disease treatment
Protalix BioTherapeutics, a leader in the development of innovative therapies for rare diseases, has announced a significant update…